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We report a cystic fibrosis (CF) subject with extensive, central venous catheter-associated thrombosis and sustained elevation of factor
VIII to levels normally associated with significantly increased risks of deep venous thrombosis. To determine the potential significance of this
finding, the prevalence of elevated factor VIII levels in 22 adults with CF was investigated. Mean (S.D.) factor VIII level was 177 (43) U/dl,
with 77% of subjects having levels >150U/dl. The high prevalence of elevated factor VIII levels questions the significance of this finding in
CF subjects with catheter-related thrombosis.
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Intravenous antibiotic therapy, often delivered via totally
implantable venous access devices (TIVAD’s), is an
essential component of the management of CF pulmonary
disease. Although TIVAD’s in CF patients are generally safe
and reliable, long term series report associated complica-
tions in approximately half of those with these devices [1–
3], the most common being either thrombosis or catheter
occlusion. Reported rates of thrombosis in larger series vary
between 3.5% [2] and 16% [3] and catheter occlusion
(which may be the end-result of asymptomatic thrombosis)
in 12% [2] to 23% [4]—some authors have suggested that
thought be given to prophylactic anticoagulation with either
low-dose warfarin [3] or aspirin [5].
Two recent studies have reported unexpectedly high
prevalences of thrombophilia [6,7], in up to 53% of1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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and protein C deficiency were substantially higher than
reported incidences in the general population and in one [6],
the prevalence of lupus anticoagulant and antithrombin also
appeared increased. However, neither study evaluated
Factor VIII levels, elevated levels of which have been
shown to be a common risk factor for deep venous
thrombosis in the general population [8,9]. Evidence
suggests that these levels are increased independently of
inflammation [10].
We identified persistently elevated factor VIII levels in a
CF subject who presented with extensive, TIVAD-related
thrombosis. Recent evidence [9] implicated elevated factor
VIII levels in the subject’s thrombotic events and advice
from haematology colleagues suggested that he required
anticoagulation. However, the decision to anticoagulate a
CF subject is not trivial given the risks of life-threatening
bleeding, with massive haemoptysis reported to occur in
almost 1% of all CF subjects each year (and 4% of subjects
over a 10-year period) [11]. Further, we were concerned that
elevated factor VIII levels may merely reflect the chronic
pulmonary inflammatory process that characterises this
disease. Therefore, in an attempt to determine the signifi-5 (2006) 201 – 204ed by Elsevier B.V. All rights reserved.
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prevalence was investigated in a group of CF subjects,
including relationships with inflammation and disease
severity.Fig. 1. Bilateral upper limb venography demonstrating occlusion of both
internal jugular and innominate veins and collateral drainage to the superior
vena cava.2. Case report
An 18-year-old male with CF was referred to our hospital
for insertion of a TIVAD. He had mild to moderate lung
disease with an FEV1 of 69% of predicted and his body
mass index (BMI) was 20kg/m2. His CF was complicated
by chronic pulmonary Pseudomonas aeruginosa colonisa-
tion and pancreatic insufficiency. His medications com-
prised nebulised recombinant deoxyribonuclease (DNase),
nebulised colistin, inhaled budesonide and salbutamol, oral
pancreatic enzyme supplementation, and oral multivitamins.
He had required up to four courses of intravenous
antibiotic therapy per year for exacerbations of his
pulmonary disease. Intravenous antibiotics delivered
through peripheral cannulae and peripherally inserted
central intravenous catheters had repeatedly resulted in
cannula occlusion within 24 to 36h of insertion and at
11years of age he had his first TIVAD inserted into the right
subclavian vein. This device had occluded approximately
12months later and he had a second device placed on the
left side aged 12years. This had functioned for several
years, becoming occluded when he was 16years old, and
was removed 12months before referral to us. At that time a
surgeon had been unable to insert a new TIVAD into the
right subclavian vein.
The patient had no current symptoms suggesting
exacerbation of his pulmonary disease. He had no signs of
chronic liver disease or portal hypertension, and no clinical
signs of SVC obstruction. FEV1/FVC was 3.2/5.13 (FEV1
69% predicted).
Doppler ultrasonography of his upper limbs and chest
demonstrated bilaterally occluded internal jugular veins
with patent flow in both subclavian veins. TIVAD insertion
was attempted, however the surgeon was unable to advance
the catheter despite obtaining subclavian venous access on
both sides. Subsequent bilateral upper limb venography
demonstrated bilateral internal jugular vein occlusion, with
bilateral medial occlusion of the innominate veins and
extensive surrounding collateralization to the superior vena
cava (Fig. 1). The radiographic appearances and clinical
history were consistent with longstanding obstruction and
organized thrombus.
Thrombophilia screen demonstrated a marked elevation of
his serum factor VIII levels (204U/dl, ref. range 50–150),
and heterozygosity for the methylenetetrahydrofolate reduc-
tase (MTHFR) C177T gene polymorphism. Fasting serum
homocysteine was subsequently normal as were other factors
(Factor XII, protein C, protein S, antithrombin III, prothrom-
bin mutation 20210A, Factor V Leiden, anticardiolipin
antibodies and lupus anticoagulant). D-dimer level was notperformed. Repeat factor VIII levels 4months later remained
elevated at 205U/dl. Neither of the subject’s parents had
elevations of Factor VIII levels, presence of the MTHFR
C177T gene polymorphism or hyperhomocystinemia.
Haematology opinion suggested that long-term warfarin
therapy be considered however we were concerned about
the possible contribution of pulmonary inflammation to the
factor VIII levels, particularly in view of the risks of
pulmonary bleeding in CF. On the basis of the subsequent
finding of a high incidence of elevated levels of factor VIII
in our CF population, and in consultation with the subject
and his family, anticoagulation was withheld.3. Methods
A cross-sectional analysis of adult CF patients was
undertaken. Venous blood was drawn for Factor VIII levels
and serum CRP after being seated quietly for 30min.
Spirometry was performed with a Micro spirometer (Micro
Medical, Rochester, Kent) and the subjects were weighed.
Retrospective chart review was undertaken to ascertain the
number of days of intravenous antibiotics (IV’s) received by
each patient in the preceding 12months. Factor VIII levels
were determined by one stage APTT based clotting assay
using standard techniques and serum CRP by turbidimetric
immunoassay (Wako Chemicals, Neuss, Germany). Statis-
tical analyses were performed using SPSS for Windows
release 11.0.0 (SPSS Inc., Chicago). CRP was log-trans-
formed for correlations and regression analyses. Univariate
analyses were performed by Pearson’s method and multiple
linear regression analysis was used to model associations for
continuously scaled dependent variables. Comparisons
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for CRP, T-tests for normally distributed data and Pearson’s
chi square test for dichotomous variables.4. Results
Twenty-two unselected adult CF subjects (10 males),
representing both outpatients and inpatients from a total
clinic population of approximately 80, mean (TS.D.) age 26
(T12.5) years and percent-predicted forced expiratory
volume in 1s (FEV1) 47.3 (T18.8)% were evaluated. Five
patients were receiving IV’s for infective exacerbations of
pulmonary disease and three further patients were clinically
well but receiving routine, scheduled three-monthly courses.
Only two subjects had previous documented TIVAD
occlusion, the index case having an initial Factor VIII level
of 204U/dl (205 on repeat testing) and the second subject an
initial level of 158 (105 on repeat). Mean (TS.D.) factor VIII
for the entire group was 177 (T43) U/dl and 17 subjects
(77%) had elevated levels (>150U/dl). Persistently elevated
Factor VIII levels were seen in two of the three subjects who
had repeat levels performed at least 3months later. Median
(range) CRP in 21 subjects was 11.6 (<2 to 101) mg/l (ref.
range <6), 10 subjects having elevated levels and the
remaining 11 were normal. Two subjects had documented
liver disease, and both had elevations of factor VIII (164 and
179). No subject had nephrotic syndrome or autoimmune
disease.
There were no significant relationships between factor
VIII levels and log-transformed CRP on univariate analysis
(correlation coefficient 0.3, p =0.187), nor markers of
disease severity (percent predicted FEV1, body-mass in-
dex/BMI, number of days of IV’s in the precedingFig. 2. Comparison of Factor VIII in CF subjects with normal and elevated
CRP levels (CF—cystic fibrosis, CRP—C-reactive protein.)12months). Multiple linear regression analysis incorporat-
ing factor VIII as the dependent variable and log-trans-
formed CRP, percent-predicted FEV1, BMI, days of IV’s in
the prior 12months and the current presence of infective
exacerbation as independent variables failed to show any
significant associations with factor VIII levels. The five
subjects with normal serum Factor VIII levels did not differ
from those with elevated levels for any variable including
CRP. There was no significant difference in factor VIII
levels between those subjects with normal CRP levels and
those with CRP greater than 6mg/l (172.8T44.3 vs.
186.3T43U/dl, p =0.49, 95% CI 26.4 to 53.4; see Fig. 2).5. Discussion
Elevated factor VIII has recently emerged as a risk factor
for venous thrombosis in the general population and appears
to be nearly as common as factor V Leiden. It has been
implicated in approximately 20% of patients with throm-
botic events [8,9], and is an important risk factor for
recurrent thromboses, particularly at levels above the 90th
centile [9]. Plasma levels above 150U/dl are associated with
five times the risk of venous thrombosis, with a stepwise
increase in risk associated with increasing absolute levels
[12]. The combination of elevated levels of both factor VIII
levels and D-dimer in children presenting with venous
thrombosis has been shown to predict a poor outcome of
venous thrombosis [13]. While the underlying pathogenesis
is not known, there is evidence for familial clustering [14].
Factor VIII is an acute phase reactant, however in patients
who develop venous thrombosis, factor VIII levels appear to
be constitutively increased and persist over time, rather than
being secondary either to inflammation or thrombosis itself
[8–10,12]. The rationale for the current evaluation of Factor
VIII levels in a subset of our CF population was intended to
provide guidance as to the potential therapeutic implications
of elevated factor VIII levels in our index case, given the
absence of literature in this population. The finding of a
high prevalence of apparently coincidental elevations of
factor VIII levels provided some evidence to support our
decision to withhold anticoagulation.
The high prevalence of elevated levels of factor VIII in
this small, unselected group of CF subjects suggests
cautious interpretation of elevated factor VIII levels as a
potential thrombophilic factor in CF subjects. In our small
series, 50% of subjects had levels above 175U/dl. In
contrast, in Kraaijenhagen et al.’s study [12], 10% of
controls and only 19% and 33% of subjects with single and
recurrent thrombosis respectively had similar levels. The
current evaluation was not intended to answer the question
of potential relationships between inflammation, elevated
factor VIII levels and risks of catheter-related thrombosis in
CF subjects (and indeed was not designed or powered to do
so), but merely to attempt to contextualize the finding of
elevated levels in our index subject. Given the uncontrolled
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conclusions about the aetiology of elevated factor VIII in
this population, however the results obtained raise some
interesting questions, particularly in light of the recent
reports suggesting increased prevalence of a number of
other thrombophilic states in CF children [6,7].
While intuitively it seems likely that the high proportion of
our CF patients with elevated factor VIII levels reflects the
systemic inflammatory response that is a feature of this
disease, our data failed to show evidence of any relationship
with CRP. Even among those subjects with normal CRP
levels, factor VIII was elevated in the majority, to levels
similar to those in the group with elevated CRP. The reasons
for the lack of any demonstrable relationship between factor
VIII and CRP may merely reflect the aforementioned
limitations of this small, uncontrolled analysis. Alternatively,
prior work suggests that factor VIII is a more sensitive acute-
phase reactant than CRP [15] and factor VIII levels may
increase earlier than CRP; we did not measure alternative
inflammatory markers. It may be that elevated factor VIII
levels in the CF population are the result of a number of
influences rather than inflammation alone, as both liver
disease and vitamin K deficiency may influence levels of
factor VIII activity [16]. While only two subjects in the
current group had documented liver disease, it is possible that
unrecognized subclinical liver disease affects factor VIII.
Finally, we did not assess levels of von Willebrand Factor
(vWF), which is known to explain some of the genetically
determined variation in factor VIII levels [17].
The consistency between recent reports describing
increased prevalence of a number of thrombophilic factors
among CF subjects [6,7] suggests that there may be a
common underlying predisposing factor—we cautiously
postulate that systemic inflammation, perhaps in combina-
tion with other factors, is responsible rather than true
thrombophilia.
In conclusion, in this small group of CF patients we have
observed a high incidence of elevated Factor VIII levels,
questioning the significance of such a finding in relation to
risk of thrombosis in these subjects. In order to be able to
meaningfully apply the results of studies evaluating the
thrombotic risks related to elevated factor VIII levels, data
specifically evaluating diseased subjects are needed. The
determinants and implications of elevated factor VIII levels
(and other blood markers of thrombophilia), in subjects with
CF who present with catheter-related thrombosis, remain
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